Modulation of Transforming Growth Factor-beta (TGF-beta ) Signaling by Endogenous Sphingolipid Mediators*

Madoka SatoDagger §, Margaret MarkiewiczDagger , Masoyoshi YamanakaDagger , Alicja Bielawska, Cungui Mao||, Lina M. Obeid||, Yusuf A. Hannun, and Maria TrojanowskaDagger **

From the Dagger  Division of Rheumatology and Immunology and the  Department of Biochemistry and Molecular Biology, Medical University of South Carolina and the || Division of General Internal Medicine, Ralph H. Johnson Veterans Affairs Hospital, Charleston, South Carolina 29425

Received for publication, November 12, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Transforming growth factor-beta (TGF-beta ) is a multifunctional growth factor that plays a critical role in tissue repair and fibrosis. Sphingolipid signaling has been shown to regulate a variety of cellular processes and has been implicated in collagen gene regulation. The present study was undertaken to determine whether endogenous sphingolipids are involved in the TGF-beta signaling pathway. TGF-beta treatment induced endogenous ceramide levels in a time-dependent manner within 5-15 min of cell stimulation. Using human fibroblasts transfected with a alpha 2(I) collagen promoter/reporter gene construct (COL1A2), C6-ceramide (10 µM) exerted a stimulatory effect on basal and TGF-beta -induced activity of this promoter. Next, to define the effects of endogenous sphingolipids on TGF-beta signaling we employed ectopic expression of enzymes involved in sphingolipid metabolism. Sphingosine 1-phosphate phosphatase (YSR2) stimulated basal COL1A2 promoter activity and cooperated with TGF-beta in activation of this promoter. Furthermore, overexpression of YSR2 resulted in the pronounced increase of COL1A1 and COL1A2 mRNA levels. Conversely, overexpression of sphingosine kinase (SPHK1) inhibited basal and TGF-beta -stimulated COL1A2 promoter activity. These results suggest that endogenous ceramide, but not sphingosine or sphingosine 1-phosphate, is a positive regulator of collagen gene expression. Mechanistically, we demonstrate that Smad3 is a target of YSR2. TGF-beta -induced Smad3 phosphorylation was elevated in the presence of YSR2. Cotransfection of YSR2 with wild-type Smad3, but not with the phosphorylation-deficient mutant of Smad3 (Smad3A), resulted in a dramatic increase of COL1A2 promoter activity. In conclusion, this study demonstrates a direct role for the endogenous sphingolipid mediators in regulating the TGF-beta signaling pathway.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Transforming growth factor-beta (TGF-beta )1 is a member of a large family of growth factors with diverse functions in embryonic and adult tissues (1). TGF-beta plays a critical role in regulating immune cell function, epithelial cell growth, and extracellular matrix deposition (2). Abnormal TGF-beta signaling has been implicated in the pathogenesis of a number of diseases, including cancer and fibrosis (3). TGF-beta signals through a heteromeric receptor complex of type I and type II receptor serine-threonine kinases. Intracellular signal transducers termed Smads transmit signals from the receptor to the nucleus. The members of the Smad family have been divided into three functional subgroups: receptor-regulated Smads (R-Smads), the common mediator Smads (co-Smads), and inhibitory Smads (I-Smads). R-Smads (Smad2 or -3) are phosphorylated on a conserved SSXS motif by the activated type I receptor leading to their dissociation from the receptor. Subsequently, they form heterocomplexes with co-Smads and upon translocation into the nucleus contribute to transcriptional regulation of the target genes (1). A Smad-interacting membrane-bound protein SARA (Smad anchor for receptor activation) facilitates binding of the Smad2/3 to the activated type I receptor (4). Recent studies suggest that interaction of SARA with Smads occurs in early endosomes (5, 6). Another endosomal FYVE domain protein, Hgs, has also been shown to cooperate with SARA in recruiting Smad2 and Smad3 to the activin receptor complex (7). Interestingly, translocation of Smads to the nucleus can be blocked by phosphorylation of the linker region of R-Smads by Ras/extracellular signal-regulated kinases (ERKs) (8), suggesting that Smads can be directly targeted by other signaling pathways. There is also increasing evidence for cross-talk between TGF-beta and other signaling pathways (9).

Sphingolipids, in addition to their role as structural molecules of the plasma membrane, are now recognized as important bioactive mediators of a variety of cellular processes (10-12). In particular, biologic functions of ceramide, sphingosine, and their phosphates have been extensively studied. Intracellular ceramide is primarily generated via hydrolysis of sphingomyelin by a family of sphingomyelinases. In addition, ceramide can be formed from sphingosine by ceramide synthase. Sphingosine can be further converted to sphingosine 1-phosphate (S1P) by the action of sphingosine kinase (SPHK1). On the other hand, S1P phosphatase dephosphorylates S1P back to sphingosine (Fig. 1). The yeast S1P phosphatase, YSR2 (yeast sphingosine resistance gene), which has a high degree of specificity, has recently been cloned and characterized (13). It has been shown that overexpression of YSR2 in yeast increased ceramide formation. Conversely, deletion of YSR2 decreased ceramide levels (14). The biosynthetic pathways of sphingoid bases, their phosphates, and ceramide are conserved for the most part from yeast to mammals. It was shown that mammalian S1P phosphatase was able to substitute for YSR2 when expressed in mutant yeast lacking YSR2 function (15). Thus, it has been proposed that S1P phosphatase may play an important role in altering the balance between ceramide and intracellular S1P. Significantly, ceramide and S1P appear to have antagonistic functions, particularly in the regulation of cell growth. Ceramide, which is induced by inflammatory cytokines, various damaging agents, and stress signals, seems to be mainly associated with cell growth arrest and apoptosis, whereas intracellular S1P has been shown to promote cell proliferation (10, 11). It is important to note that the effects of ceramide and S1P on cell growth and other cellular functions are cell type-specific.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 1.   Schematic view of sphingolipid metabolism. SM, sphingomyelin; SMase, sphingomyelinase; S1P, sphingosine 1-phosphate; GlcCer, glucosylceramide.

Previous studies have suggested that ceramide may also be involved in regulation of collagen metabolism. It was shown that C2-ceramide and sphingomyelinase inhibit collagen gene expression in hepatic stellate cells and dermal fibroblasts (16, 17). Furthermore, C2-ceramide suppressed alpha 2(I) collagen (COL1A2) promoter activity (16). Because elevated collagen production is associated with fibrotic diseases and TGF-beta is a primary inducer of collagen, this study was undertaken to examine the possible role of sphingolipids in TGF-beta regulation of collagen production. Using exogenous S1P and C6-ceramide and enzymatic manipulation of endogenous sphingolipids, we demonstrate that intracellular sphingolipids modulate the TGF-beta signaling pathway. Furthermore, we provide evidence that the effects of sphingolipids are Smad3-dependent. This study establishes for the first time direct functional interaction between TGF-beta and sphingolipid signaling pathways.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cell Cultures-- Foreskin fibroblast cultures were established from newborn foreskins obtained from delivery suites of local hospitals. Tissue was dissociated enzymatically by 0.25% collagenase type I (Sigma) and 0.05% DNase (Sigma) in DMEM with 10% fetal bovine serum. COS, Mv1Lu, and HEK 293 cells were obtained from the American Type Culture Collection. Cells were grown in DMEM supplemented with 10% fetal bovine serum.

Plasmid Constructs-- The COL1A2-luciferase construct contains sequences from -353 to +58 bp of the human COL1A2 promoter (18) fused to the luciferase reporter gene (pGL2 basic, Promega). Cloning of YSR2 has been described previously (13, 14). The open reading frame of YSR2 was recloned into KpnI and EcoR1 sites of pcDNA3.1 (Invitrogen). The EGFP coding sequence was amplified from pEGFP-N1 (Clontech, Palo Alto, CA) and inserted into HindIII and KpnI sites upstream of YSR2. p3TP-Lux was a gift from J. Massagué (Memorial Sloan-Kettering Cancer Center, New York, NY). The expression construct for the constitutively active form of TGF-beta type I receptor (HA-Tbeta RI(TD)) was provided by K. Miyazono (University of Tokyo). Expression vectors for Smad3 and Smad3A, which carry three carboxyl-terminal serine-to-alanine substitutions, were gifts from H. Lodish (Whitehead Institute, MA). SPHK1a was subcloned as described by Olivera et al. (19) into pcDNA3.1 vector.

Adenoviral Constructs-- Adenoviral vectors expressing YSR2 and green fluorescent protein (GFP) were generated using a published protocol (20). Briefly, the cDNA encoding YSR2 was cloned into the shuttle vector pAdTRACK-CMV, which contains a GFP expression cassette driven by a separate CMV promoter. The shuttle vector containing YSR2 was cotransformed into Escherichia coli BJ5183 cells with the AdEasy-1 adenoviral backbone plasmid, which lacks the E1 and E3 regions of the adenoviral genome. Linearized recombinant plasmid DNA was transfected into 293 cells, an adenoviral packaging cell line, using the FuGENE 6 transfection reagent (Roche Molecular Biochemicals) to generate the recombinant adenovirus expressing YSR2 and GFP from separate CMV promoters (AdYSR2). An adenovirus expressing GFP alone (AdGFP) was generated via the same method for use as a control vector.

Transient Transfection and Luciferase Assay-- For transient transfection, 60-80% confluent cells in 6-well plates were transfected using FuGENE 6 transfection reagents (Roche Molecular Biochemicals) following the manufacturer's recommendations. After transfection, cells were incubated for 20 h and stimulated where indicated for an additional 24 h with TGF-beta (R & D Systems, Minneapolis, MN), C6-ceramide, S1P, or sphingosine (synthesized as described in Ref. 21). Luciferase activities in the cell lysates were measured with a dual luciferase reporter assay system (Promega).

RNA Preparation and Northern Blot Analysis-- Human fibroblasts (5 × 104) were plated in 10% fetal calf serum/DMEM in 6-well plates. Next day, cells were transfected using FuGENE 6 reagent with either empty vector or YSR2. 20 h after transfection, the number of GFP-positive cells was visually determined using a Zeiss Axiovert 35 microscope. Efficiency of transfection in dermal fibroblasts varied from 5 to 15%. Experiments in which efficiency of transfection was below 10% were not continued. Medium was changed to 1% fetal bovine serum/DMEM, and TGF-beta 1 (5 ng/ml) was added for an additional 24 h. Total RNA was extracted and analyzed by Northern blot as described previously (22). Filters were sequentially hybridized with radioactive probes for COL1A1, COL1A2, and 18 S ribosomal RNA. The filters were scanned with a PhosphorImager (Amersham Biosciences).

Immunoprecipitation and Immunoblotting-- For determination of phosphorylation levels of ectopically expressed Smad3, cell lysates were subjected to immunoprecipitation with the anti-FLAG antibody followed by adsorption to protein G-Sepharose (Amersham Biosciences). Precipitates were separated by SDS-PAGE. After immunoblotting with the anti-phosphoserine antibody (Zymed Laboratories Inc., South San Francisco, CA), the membranes were subjected to re-blotting with anti-FLAG (M2, Sigma) antibody to confirm levels of expression of the FLAG-tagged Smad3 protein. To determine levels of expression of the receptors, aliquots of cell lysates were subjected to SDS-PAGE and immunoblotting with anti-HA (Santa Cruz Biotechnology, Santa Cruz, CA). To determine the kinetics of phosphorylation of endogenous Smad3, Mv1Lu cells or dermal fibroblasts were treated with TGF-beta 1 (2.5 ng/ml) for various time intervals. Cell lysates were subjected to immunoprecipitation with the anti-Smad2/3 antibody (N-19, Santa Cruz Biotechnology) followed by adsorption to protein G-Sepharose. Western blotting was performed using an anti-phosphoserine antibody. As loading control, membranes were subjected to re-blotting using an antibody against Smad3 (FL-425, Santa Cruz Biotechnology).

Assay of Sphingosine Kinase Activity-- Foreskin fibroblasts were transiently transfected with either SPHK1a or empty vector. After a 24-h incubation in DMEM/1% fetal bovine serum, cells were harvested and lysed in buffer containing 20 mM Tris, pH 7.4, 20% glycerol, 1 mM beta -mercaptoethanol, 1 mM EDTA, 1 mM sodium orthovanadate, 40 mM beta -glycero-phosphate, 15 mM NaF, 10 µg/ml leupeptin, aprotinin, and soybean trypsin inhibitor. Sphingosine kinase activity was determined in the presence of 50 µM sphingosine, dissolved in 5% Triton X-100 (final concentration 0.25%), and [32P]ATP (10 µCi, 1 mM) containing MgCl2 (10 mM) as described in Ref. 23. The labeled S1P was identified by thin layer chromatography with 1-butanol/ethanol/acetic acid/water (80:20:10:20) and visualized by autoradiography.

Assay of S1P Phosphatase Activity-- Phosphatase activity was measured as previously described (15). Briefly, HEK 293 cells were transfected with either YSR2 or empty vector. Forty-eight hours after transfection, cells were lysed in buffer A (100 mM Hepes, pH 7.5, containing 10 mM EDTA, 1 mM dithiothreitol, and 10 µg/ml each leupeptin, aprotinin, and soybean trypsin inhibitor), and cells were scraped on ice. Cells were subsequently freeze-thawed seven times, then centrifuged at 100,000 × g for 1 h. Supernatants were removed, and the membrane fractions were resuspended in 200 µl of buffer A and homogenized. 32P-labeled S1P was prepared by in vitro phosphorylation of sphingosine using cell lysates obtained from 293 cells overexpressing SPHK1. Alternatively, D-erythro-[4,5-3H]dihydrosphingosine-1-phosphate (ARC, Inc.) was used as a substrate. Similar results were obtained with both substrates. S1P phosphatase activity was measured by adding 32P-labeled S1P to 20 µg of membrane preparations in 200 µl of buffer A and incubated for 30 min at 30 °C. The assay was terminated by adding 20 µl of 1N HCl, and lipids extracted with 0.8 ml of chloroform/methanol/HCl (100:200:1). To separate phases, 0.24 ml of chloroform and 0.24 ml of 2 M KCl were added. After centrifugation, 100 µl of the aqueous layer was counted by liquid scintillation. Remaining 32P-labeled S1P was extracted and analyzed by TLC.

Measurment of Cellular Ceramide-- Mv1Lu cells or dermal fibroblasts were grown to near confluence, and culture medium was changed to serum-free DMEM for 24 h, followed by stimulation with TGF-beta 1 (2.5 ng/ml) for various time intervals. Lipids were then extracted with chloroform/methanol/water and processed for determination of ceramide as described (24).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

TGF-beta Stimulates Endogenous Ceramide Levels-- Modulation of ceramide levels by a variety of stimuli has been observed in many cell types; however, only limited information is currently available regarding TGF-beta regulation of ceramide (25). To examine whether ceramide is involved in TGF-beta signaling, we measured ceramide levels in cells treated with TGF-beta for various time intervals. Ceramide measurements were performed in human dermal fibroblasts and in Mv1Lu cells. Both cell types responded in a similar manner with a rapid increase of the ceramide levels in response to TGF-beta . As shown in Fig. 2A, ceramide increased 5 min after TGF-beta addition, peaked by 10 min, and very slowly declined over the next 2 h. We also examined phosphorylation of Smad3 in cells treated with TGF-beta for the same time intervals (Fig. 2B). Detectable phosphorylation of Smad3 occurred at 10 min after TGF-beta addition, with the peak phosphorylation between 20-60 min and a decline at 120 min. These results indicate that TGF-beta treatment leads to a relatively rapid induction of endogenous ceramide. Furthermore, generation of ceramide preceded Smad3 phosphorylation, raising the possibility that ceramide may be involved in TGF-beta signaling.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 2.   TGF-beta induces endogenous ceramide levels and Smad3 phosphorylation with similar kinetics. Mv1Lu cells were treated with TGF-beta (2.5 ng/ml) for the indicated time intervals. The measurements of ceramide levels and detection of phosphorylated Smad3 were performed as described under "Materials and Methods." Values represent the mean ± S.D. of three independent experiments.

Exogenous S1P and C6-ceramide Modulate TGF-beta -dependent COL1A2 Promoter Activity-- Because our laboratory is particularly interested in defining TGF-beta signaling pathways relevant to fibrosis, we utilized a well characterized COL1A2 promoter reporter construct to delineate the role of ceramide in TGF-beta regulation of matrix genes (18, 22, 26). It has been previously shown that TGF-beta stimulation of this promoter is Smad3-dependent (27, 28). We first examined the effects of exogenously added sphingolipids on the basal and TGF-beta -dependent COL1A2 promoter activity. Dermal fibroblasts were transfected with the COL1A2 promoter and treated with S1P (10-30 µM), C6-ceramide (10-50 µM), and sphingosine (1 µM) in the presence or absence of TGF-beta . S1P at micromolar concentrations slightly stimulated basal and TGF-beta -induced COL1A2 promoter activity (Fig. 3A), whereas nanomolar doses of S1P had no effect on the COL1A2 promoter (data not shown). C6-ceramide (10 µM) stimulated COL1A2 promoter activity with an effect comparable with that of TGF-beta , a known inducer of collagen gene transcription (Fig. 3B). Simultaneous addition of C6-ceramide (10 µM) and TGF-beta resulted in a further increase of the COL1A2 promoter activity. On the other hand, C6-ceramide at a higher concentration (50 µM) did not affect basal promoter levels and decreased TGF-beta -induced COL1A2 promoter activity (Fig. 3B). Sphingosine (1 µM) had no effect on the COL1A2 promoter activity in the presence or absence of TGF-beta (Fig. 3C). Higher concentrations of sphingosine were toxic. These experiments suggest that sphingolipids may be modulators of the basal and TGF-beta -dependent COL1A2 promoter activity in dermal fibroblasts.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 3.   S1P and C6-ceramide stimulate COL1A2 promoter activity in fibroblasts, whereas sphingosine has no effect. Foreskin fibroblasts were transiently transfected with the COL1A2 promoter construct (1 µg) for 20 h. Cells were subsequently treated with S1P (A), C6-ceramide (B), or 1 µM sphingosine (C) alone or in combination with TGF-beta (5 ng/ml) for 24 h. Values represent the mean ± S.E. of five independent experiments performed in duplicate (A) or three independent experiments in duplicate (B and C).

Interestingly, ceramide had both stimulatory (at lower doses) and inhibitory (at higher doses) effects. One possible interpretation of these results is based on the current view of the dynamic balance between intracellular levels of ceramide, sphingosine, and S1P (10). Because the relative ratio of endogenous ceramide and S1P is tightly controlled, the stimulatory effect of high concentrations of S1P may be because of its conversion to ceramide. Also, the failure of S1P to act in nanomolar range argues against its effects being mediated through the S1P receptors and further supports intracellular action, which would include metabolic interconversion as a distinct possibility. Conversely, inhibitory effects of high doses of ceramide may reflect its metabolism to S1P or other inhibitory intermediates. Together, the experiments using exogenous sphingolipids suggest that balance between components of sphingolipid pathway may be important for collagen gene regulation.

YSR2 and TGF-beta Synergize to Induce COL1A2 Promoter-- To gain more understanding into the nature of endogenous sphingolipids involved in TGF-beta signaling, we took advantage of the availability of recombinant enzymes involved in regulation of the balance between S1P and ceramide (see Fig. 1). First, we utilized YSR2 to generate endogenous ceramide. YSR2 specifically dephosphorylates S1P to sphingosine, which is then converted to ceramide. Control experiments indicated that cell lysates prepared from cells ectopically expressing YSR2 contained higher levels of S1P phosphatase activity as compared with cell lysates obtained from cells expressing empty vector (Fig. 4A). We also determined that ectopic expression of YSR2 elevates endogenous ceramide levels (Fig. 7D). Overexpression of YSR2 in dermal fibroblasts led to a modest but consistent induction of the COL1A2 promoter activity. Significantly, TGF-beta stimulation of this promoter was greatly potentiated by the presence of YSR2 (Fig. 4B). To determine whether activation by YSR2 is specific for the COL1A2 promoter or whether YSR2 is a general coactivator of the TGF-beta pathway, we used a TGF-beta -responsive artificial reporter system (p3TP-Lux promoter). YSR2 induced basal activity of the p3TP-Lux promoter and synergized with TGF-beta in activation of this promoter, suggesting a general effect of YSR2 on the TGF-beta signaling pathway (Fig. 4C).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 4.   YSR2 cooperates with TGF-beta to activate COL1A2 promoter. A, phosphatase activity was measured in cell lysates obtained from 293 cells transiently transfected with YSR2 (see "Materials and Methods" for details). Values represent the mean ± S.D. of three independent experiments. Values from vector-transfected cells were arbitrarily set at 100%; YSR2-transfected cells indicate increases over control. B, foreskin fibroblasts were transiently transfected with 0.1 µg of YSR2 expression vector along with the COL1A2 promoter construct (0.9 µg) or (C) the p3TP-Lux construct (0.9 µg). Luciferase activity was determined following treatment with TGF-beta (5 ng/ml) for 24 h. Values represent the mean ± S.E. of three independent experiments done in duplicate.

We next examined the effects of overexpressing SPHK1 on COL1A2 promoter activity. This enzyme generates S1P by phosphorylating sphingosine. Control experiments indicated that cell lysates prepared from cells ectopically expressing SHPK1 contained higher levels of SPHK1 activity (Fig. 5A). Overexpression of SHPK1 in dermal fibroblasts slightly decreased both basal and TGF-beta -stimulated COL1A2 promoter activity (Fig. 5B). Together, these experiments indicate that perturbation of the intracellular sphingolipid-ceramide pathway has both positive and negative effects on TGF-beta signaling, such that tilting the balance from S1P to ceramide exerts a pronounced stimulatory effect, whereas tilting the balance from ceramide S1P induces a modest inhibitory effect.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 5.   SPHK inhibits basal and TGF-beta -stimulated COL1A2 promoter activity. A, foreskin fibroblasts were transiently transfected with either 0.1 µg of SPHK1a (SPHK) or empty vector (control). Twenty-four hours post-transfection, sphingosine kinase activity in cell lysates was determined using 50 µM sphingosine and [32P]ATP (10 µCi, 1 mM). Analysis of [32P]S1P was performed by thin layer chromatography. B, foreskin fibroblasts were transiently transfected with 0.1 µg of SPHK1 expression vector along with the COL1A2 promoter construct (0.9 µg). Luciferase activity was determined following treatment with TGF-beta (5 ng/ml) for 24 h. Values represent the mean ± S.E. of three independent experiments done in duplicate.

YSR2 Induces Endogenous Collagen Type I Gene Expression-- Next, we examined the effects of the ectopically expressed YSR2 on expression levels of COL1A1 and COL1A2 mRNAs in human dermal fibroblasts transiently transfected with YSR2. Both COL1A1 and COL1A2 mRNAs were significantly increased in cells transfected with YSR2 as compared with cells transfected with empty vector (Fig. 6). Depending on the individual cell line, stimulation of COL1A1 by YSR2 varied from 1.6- to 9.9-fold, whereas stimulation by TFG-beta varied from 1.7- to 8.8-fold. When both stimuli were present, an additional modest increase was observed (2.2- 11.3-fold). It should be noted that in human dermal fibroblasts autocrine TGF-beta signaling pathway is operational and contributes to basal collagen gene expression (29). Thus, increased COL1A1 and COL1A2 mRNA levels in cells transfected with YSR2 may reflect cooperation between YSR2 and low levels of endogenous TGF-beta signaling pathway. Presently, we cannot exclude that other signaling pathways that are involved in collagen gene regulation are also affected by YSR2.


View larger version (66K):
[in this window]
[in a new window]
 
Fig. 6.   YSR2 stimulates endogenous type I collagen gene expression. Dermal fibroblasts were transiently transfected with YSR2 or empty vector and analyzed by Northern blot as described under "Materials and Methods." Where indicated, TGF-beta (5 ng/ml) was added for 24 h. Efficiency of transfection varied between 10-15%. The experiment was performed nine times; a representative three experiments using independently isolated human fibroblast cell lines are shown.

YSR2 Regulates Smad3-- Smad2 and Smad3 are mediators of TGF-beta signaling. Furthermore, we have previously shown that Smad3 mediates TGF-beta stimulation of the COL1A2 promoter in dermal fibroblasts (28). Therefore, we next examined the effects of YSR2 on Smad3 stimulation of the COL1A2 promoter. Transfection with Smad3 or YSR2 alone resulted in induction of the promoter activity. However, cotransfection of the COL1A2 promoter with Smad3 and YSR2 led to a dramatic increase in collagen promoter activity (Fig. 7A). Interestingly, cotransfection of Smad3A (a mutant of Smad3 that carries three carboxyl-terminal serine-to-alanine substitutions) (30) also produced a modest stimulatory effect. This may be because of activation of endogenous Smad3, or perhaps YSR2 can enhance TGF-beta signaling through an additional yet unidentified mechanism. Because recent studies have shown that nuclear import of Smad can occur without phosphorylation on the SSXS motif (31), it is possible that the action of a phosphatase facilitates dissociation of Smad3 from SARA. In any case, our data suggest that Smad3 is a major effector of YSR2.


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 7.   Smad3 is a target of YSR2 action. A, foreskin fibroblasts were transiently transfected with 0.1 µg of the wild-type Smad3 (WT) or phosphorylation-deficient Smad3, (Smad3A(3A)) or the empty vector along with the COL1A2 promoter construct (0.9 µg). Luciferase activity was determined following treatment of fibroblasts with TGF-beta (5 ng/ml) for 24 h. Values represent the mean ± S.E. of three independent experiments done in duplicate. B, TGF-beta -induced phosphorylation of Smad3 is enhanced by YSR2. COS cells were transfected with FLAG-Smad3 in the presence or absence of HA-Tbeta RI(TD) and YSR2. Cell lysates were subjected to immunoblotting with anti-phosphoserine (P-ser) antibody. The membrane was re-blotted with anti-FLAG antibody. Aliquots of cell lysates were also subjected to immunoblotting with anti-HA antibody to detect HA-Tbeta RI(TD). C, adenovirally expressed YSR2 enhances endogenous Smad2/3 phosphorylation level. Fibroblasts were transduced with control GFP-adenovirus or YSR2-adenovirus (multiplicity of infection = 70) and next day stimulated with TGF-beta . Whole cell extracts were immunoprecipitated with goat anti-Smad2/3 antibody and immunoblotted with either anti-phosphoserine antibody (upper panel) or rabbit anti-Smad3 antibody (lower panel). D, YSR2 induces endogenous ceramide levels. Ceramide levels were measured as described under "Materials and Methods" in cells transduced with control GFP-adenovirus and treated with TGF-beta or in cells transduced with YSR2-adenovirus. Values represent the mean ± S.E. of two independent experiments done in duplicate.

Because phosphorylation of C-terminal serine residues of Smad3 is necessary for its activation, we investigated the effect of YSR2 on Smad3 phosphorylation. Using COS cells, Smad3 was coexpressed with the constitutively active form of the TGFbeta receptor (Tbeta RI(TD)) in the absence or presence of YSR2. Phosphorylation of Smad3 was detected by immunoblotting using antibodies to phosphorylated serine residues. As previously shown, in the presence of Tbeta RI(TD), Smad3 phosphorylation was observed. YSR2 significantly increased Smad3 phosphorylation (Fig. 7B). This result indicates that YSR2 has an additive or synergistic effect on the intensity of the TGF-beta signaling cascade acting at the post-receptor level.

To further investigate the role of YSR2 in Smad3 activation, we ectopically expressed YSR2 in human fibroblasts using adenoviral vector. As shown in Fig. 7C, Smad2/3 was not phosphorylated in unstimulated cells but became rapidly phosphorylated in response to TGF-beta stimulation. In contrast, in cells transduced with YSR2, Smad3 became fully phosphorylated even in the absence of TGF-beta with no additional increases in phosphorylation after addition of TGF-beta . Thus, the endogenous metabolic products of YSR2 (e.g. ceramide) are capable of inducing phosphorylation of Smad3.

Previous studies have shown that overexpression of S1P phosphatase results in generation of ceramide (13-15). The endogenous levels of ceramide were measured in cells transduced either with control-GFP or with YSR2 adenoviruses and compared with cells stimulated with TGF-beta . As shown in Fig. 7D, ceramide levels were similarly induced by YSR2 overexpression or TGF-beta treatment.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The present study establishes for the first time that endogenous sphingolipids are co-regulators of the TGF-beta signaling pathway. The following observations support this conclusion. First, exogenously added C6-ceramide stimulated basal and TGF-beta -induced collagen promoter activity. Second, overexpression of the yeast S1P phosphatase had a synergistic effect with TGF-beta in activation of the collagen promoter and stimulated endogenous collagen gene. Both the yeast and the murine enzymes have been previously shown to decrease endogenous S1P levels and to increase endogenous ceramide levels (14, 15). On the other hand, TGF-beta induction of this promoter was inhibited by overexpression of SPHK1, an enzyme that promotes formation of S1P. More importantly, TGF-beta treatment induced endogenous ceramide levels, which correlated with TGF-beta -induced Smad3 phosphorylation. These results strongly suggest that ceramide is a coactivator of the TGF-beta signaling pathway and that S1P is a possible endogenous inhibitor. We have also begun to unravel the specific regulatory mechanisms involved in the interaction of sphingolipids and TGF-beta signaling pathways. We demonstrate by functional assays that the effects of YSR2 are mediated via Smad3. Consistent with these results, Smad3 phosphorylation is increased in the presence of ectopically expressed YSR2.

Our results also clarify previous observations indicating an inhibitory role of C2-ceramide in collagen production (16, 17). In our study the inhibitory effects of exogenous ceramides on COL1A2 transcription were also observed with higher doses of C6-ceramide. These observations suggest that sphingolipids may have a dual role in collagen gene regulation and that other metabolites with inhibitory functions may also be formed. S1P may be one of the metabolites with the inhibitory function. Our recent studies have shown that exogenously added S1P and lysophosphatidic acid inhibit TGF-beta stimulation of collagen mRNA stability. These effects were mediated via MEK/ERK.2 Induction of the ERK pathway was also responsible for collagen inhibition by C2-ceramide (16). Although induction of ERK pathway in response to exogenously added ceramide or SMase has been observed in several experimental systems (11), the specific intracellular mediators of this induction are presently unknown. C6-ceramide has also been shown to activate p38 pathway (32). In contrast to ERKs, p38 has been shown to cooperate with TGF-beta signaling in collagen gene stimulation (33). However, p38 does not appear to be involved in the effects observed in our study. First, Smad3 is not a direct target of p38 (34, 35). Second, stimulation of the COL1A2 promoter by YSR2 was insensitive to SB203580, a specific inhibitor of p38 (data not shown). We could also exclude stress-activated protein kinase/c-Jun NH2-terminal kinase pathway because it was shown that induction of this pathway down-regulates COL1A2 promoter in dermal fibroblasts (36). Thus, it appears that the members of the mitogen-activated protein kinase superfamily, which have been previously shown to mediate many of the ceramide effects, are not involved in the process described here.

The question remains about the nature of the interaction between the sphingolipid and TGF-beta signaling pathways. It has been demonstrated that both TGF-beta receptor type I and type II, which form homodimers in the endoplasmic reticulum, are clustered in the cell surface into discrete cellular subdomains (37, 38). Furthermore, a TGF-beta -dependent interaction between Tbeta RI and caveolin-1 has recently been described (39). Interestingly, caveolin-1 was shown to suppress TGF-beta -mediated Smad2 phosphorylation and subsequent downstream events. It is possible that ceramide may interfere with this interaction, resulting in increased Smad3 phosphorylation. This possibility will be tested in our future studies. Recent studies (5, 6) suggest that assembly of the TGF-beta signaling pathway occurs in early endosomes. Consistent with this possibility, an endosomal protein SARA has been shown to colocalize with TGF-beta receptors and recruit Smad to the receptor complex (4, 31, 40, 41). Other endosomal proteins, including Hgs (Hrs), may also contribute to TGF-beta signaling (7). It has been recently shown that ceramide binds to and activates the endosomal protease, cathepsin D (42). Thus, endosomal ceramide may facilitate interaction of the TGF-beta receptor complex with SARA and Smad3. Recent studies suggest that the lipid environment may be critical for the proper interactions of the cell surface receptors with downstream signaling molecules (43). Our data demonstrating increased Smad3 phosphorylation in cells overexpressing YSR2 are consistent with this possibility. Although the specific subcellular localization of the mammalian S1P phosphatase has not been determined, yeast S1P phosphatases have been localized to the endoplasmic reticulum (13), consistent with the possibility of interaction of this enzyme with TGF-beta receptors or components of the TGF-beta signaling pathway. In conclusion, this study demonstrates for the first time a role for the endogenous sphingolipid mediators in regulating the TGF-beta pathway. Further work is needed to delineate the specific mechanism of this interaction.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants AR 42334 (to M. T.), AR 44883 (to M. T.), GM43825 (to Y. H.), and AG16583 (to L. O.) and the RGK Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Present address: Division of Dermatology, Saiseikai Utsunomiya Hospital, 911-1 Takebayashi-machi, Utsunomiya, Tochigi 321-0974, Japan.

** To whom correspondence should be addressed: Division of Rheumatology and Immunology, Medical University of South Carolina, 96 Jonathan Lucas St., Suite 912, Charleston, SC 29425. Tel.: 843-792-7921; Fax: 843-792-7121; E-mail: trojanme@musc.edu.

Published, JBC Papers in Press, January 6, 2003, DOI 10.1074/jbc.M211529200

2 M. Sato and M. Trojanowska, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: TGF-beta , transforming growth factor-beta ; S1P, sphingosine 1-phosphate; SPHK1, sphingosine kinase; Tbeta RI, TGF-beta type I receptor; ERK, extracellular signal-regulated kinase; COL1A1, collagen alpha 1(I); COL1A2, collagen alpha 2(I); SARA, Smad anchor for receptor activation; YSR, yeast sphingosine resistance; DMEM, Dulbecco's modified Eagle's medium; GFP, green fluorescent protein; HA, hemagglutinin; MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Massague, J., and Chen, Y. G. (2000) Genes Dev. 14, 627-644[Free Full Text]
2. Massague, J. (1998) Annu. Rev. Biochem. 67, 753-791[CrossRef][Medline] [Order article via Infotrieve]
3. Blobe, G. C., Schiemann, W. P., and Lodish, H. F. (2000) N. Engl. J. Med. 342, 1350-1358[Free Full Text]
4. Tsukazaki, T., Chiang, T. A., Davison, A. F., Attisano, L., and Wrana, J. L. (1998) Cell 95, 779-791[Medline] [Order article via Infotrieve]
5. Penheiter, S. G., Mitchell, H., Garamszegi, N., Edens, M., Dore, J. J., Jr., and Leof, E. B. (2002) Mol. Cell Biol. 22, 4750-4759[Abstract/Free Full Text]
6. Panopoulou, E., Gillooly, D. J., Wrana, J. L., Zerial, M., Stenmark, H., Murphy, C., and Fotsis, T. (2002) J. Biol. Chem. 277, 18046-18052[Abstract/Free Full Text]
7. Miura, S., Takeshita, T., Asao, H., Kimura, Y., Murata, K., Sasaki, Y., Hanai, J. I., Beppu, H., Tsukazaki, T., Wrana, J. L., Miyazono, K., and Sugamura, K. (2000) Mol. Cell Biol. 20, 9346-9355[Abstract/Free Full Text]
8. Kretzschmar, M., Doody, J., and Massague, J. (1997) Nature 389, 618-622[CrossRef][Medline] [Order article via Infotrieve]
9. Wakefield, L. M., and Roberts, A. B. (2002) Curr. Opin. Genet. Dev. 12, 22-29[CrossRef][Medline] [Order article via Infotrieve]
10. Spiegel, S. (1999) J. Leukoc. Biol. 65, 341-344[Abstract]
11. Liu, G., Kleine, L., and Hebert, R. L. (1999) Crit. Rev. Clin. Lab. Sci. 36, 511-573[Medline] [Order article via Infotrieve]
12. Hannun, Y. A., and Luberto, C. (2000) Trends Cell Biol. 10, 73-80[CrossRef][Medline] [Order article via Infotrieve]
13. Mao, C., Wadleigh, M., Jenkins, G. M., Hannun, Y. A., and Obeid, L. M. (1997) J. Biol. Chem. 272, 28690-28694[Abstract/Free Full Text]
14. Mao, C., Saba, J. D., and Obeid, L. M. (1999) Biochem. J. 342, 667-675[CrossRef][Medline] [Order article via Infotrieve]
15. Mandala, S. M., Thornton, R., Galve-Roperh, I., Poulton, S., Peterson, C., Olivera, A., Bergstrom, J., Kurtz, M. B., and Spiegel, S. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 7859-7864[Abstract/Free Full Text]
16. Reunanen, N., Foschi, M., Han, J., and Kahari, V. M. (2000) J. Biol. Chem. 275, 34634-34639[Abstract/Free Full Text]
17. Hernandez-Munoz, I., de la Torre, P., Sanchez-Alcazar, J. A., Garcia, I., Santiago, E., Munoz-Yague, M. T., and Solis-Herruzo, J. A. (1997) Gastroenterology 113, 625-640[Medline] [Order article via Infotrieve]
18. Ihn, H., Ohnishi, K., Tamaki, T., LeRoy, E. C., and Trojanowska, M. (1996) J. Biol. Chem. 271, 26717-26723[Abstract/Free Full Text]
19. Olivera, A., Kohama, T., Tu, Z., Milstien, S., and Spiegel, S. (1998) J. Biol. Chem. 273, 12576-12583[Abstract/Free Full Text]
20. He, T. C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., and Vogelstein, B. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 2509-2514[Abstract/Free Full Text]
21. Bielawska, A., and Hannun, Y. A. (2000) Methods Enzymol. 311, 499-518[Medline] [Order article via Infotrieve]
22. Ihn, H., LeRoy, E. C., and Trojanowska, M. (1997) J. Biol. Chem. 272, 24666-24672[Abstract/Free Full Text]
23. Olivera, A., Kohama, T., Edsall, L., Nava, V., Cuvillier, O., Poulton, S., and Spiegel, S. (1999) J. Cell Biol. 147, 545-558[Abstract/Free Full Text]
24. Perry, D. K., Bielawska, A., and Hannun, Y. A. (2000) Methods Enzymol. 312, 22-31[Medline] [Order article via Infotrieve]
25. Goldkorn, T., and Ding, T. (1997) Adv. Exp. Med. Biol. 461-472
26. Greenwel, P., Tanaka, S., Penkov, D., Zhang, W., Olive, M., Moll, J., Vinson, C., Di Liberto, M., and Ramirez, F. (2000) Mol. Cell. Biol. 20, 912-918[Abstract/Free Full Text]
27. Zhang, W., Ou, J., Inagaki, Y., Greenwel, P., and Ramirez, F. (2000) J. Biol. Chem. 275, 39237-39245[Abstract/Free Full Text]
28. Chen, S. J., Yuan, W., Lo, S., Trojanowska, M., and Varga, J. (2000) J. Cell. Physiol. 183, 381-392[CrossRef][Medline] [Order article via Infotrieve]
29. Kawakami, T., Ihn, H., Xu, W., Smith, E., LeRoy, C., and Trojanowska, M. (1998) J. Investig. Dermatol. 110, 47-51[Abstract]
30. Liu, X., Sun, Y., Constantinescu, S. N., Karam, E., Weinberg, R. A., and Lodish, H. F. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 10669-10674[Abstract/Free Full Text]
31. Xu, L., Chen, Y. G., and Massague, J. (2000) Nat. Cell. Biol. 2, 559-562[CrossRef][Medline] [Order article via Infotrieve]
32. Ono, K., and Han, J. (2000) Cell Signal 12, 1-13[CrossRef][Medline] [Order article via Infotrieve]
33. Sato, M., Shegogue, D., Gore, E. A., Smith, E. A., McDermott, P. J., and Trojanowska, M. (2002) J. Investig. Dermatol. 118, 704-711[Abstract/Free Full Text]
34. Sano, Y., Harada, J., Tashiro, S., Gotoh-Mandeville, R., Maekawa, T., and Ishii, S. (1999) J. Biol. Chem. 274, 8949-8957[Abstract/Free Full Text]
35. Hanafusa, H., Ninomiya-Tsuji, J., Masuyama, N., Nishita, M., Fujisawa, J., Shibuya, H., Matsumoto, K., and Nishida, E. (1999) J. Biol. Chem. 274, 27161-27167[Abstract/Free Full Text]
36. Fisher, G. J., Datta, S., Wang, Z., Li, X. Y., Quan, T., Chung, J. H., Kang, S., and Voorhees, J. J. (2000) J. Clin. Invest. 106, 663-670[Abstract/Free Full Text]
37. Henis, Y. I., Moustakas, A., Lin, H. Y., and Lodish, H. F. (1994) J. Cell Biol. 126, 139-154[Abstract]
38. Gilboa, L., Wells, R. G., Lodish, H. F., and Henis, Y. I. (1998) J. Cell Biol. 140, 767-777[Abstract/Free Full Text]
39. Razani, B., Zhang, X. L., Bitzer, M., von Gersdorff, G., Bottinger, E. P., and Lisanti, M. P. (2001) J. Biol. Chem. 276, 6727-6738[Abstract/Free Full Text]
40. Wurmser, A. E., Gary, J. D., and Emr, S. D. (1999) J. Biol. Chem. 274, 9129-9132[Free Full Text]
41. Wu, G., Chen, Y. G., Ozdamar, B., Gyuricza, C. A., Chong, P. A., Wrana, J. L., Massague, J., and Shi, Y. (2000) Science 287, 92-97[Abstract/Free Full Text]
42. Heinrich, M., Wickel, M., Schneider-Brachert, W., Sandberg, C., Gahr, J., Schwandner, R., Weber, T., Saftig, P., Peters, C., Brunner, J., Kronke, M., and Schutze, S. (1999) EMBO J. 18, 5252-5263[Abstract/Free Full Text]
43. Liu, P., Wang, P., Michaely, P., Zhu, M., and Anderson, R. G. (2000) J. Biol. Chem. 275, 31648-31654[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.